191 related articles for article (PubMed ID: 11515869)
1. Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis.
Nguyen DM; Lorang D; Chen GA; Stewart JH; Tabibi E; Schrump DS
Ann Thorac Surg; 2001 Aug; 72(2):371-8; discussion 378-9. PubMed ID: 11515869
[TBL] [Abstract][Full Text] [Related]
2. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
Bisht KS; Bradbury CM; Mattson D; Kaushal A; Sowers A; Markovina S; Ortiz KL; Sieck LK; Isaacs JS; Brechbiel MW; Mitchell JB; Neckers LM; Gius D
Cancer Res; 2003 Dec; 63(24):8984-95. PubMed ID: 14695217
[TBL] [Abstract][Full Text] [Related]
3. Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin.
Nguyen DM; Chen A; Mixon A; Schrump DS
J Thorac Cardiovasc Surg; 1999 Nov; 118(5):908-15. PubMed ID: 10534697
[TBL] [Abstract][Full Text] [Related]
4. Modulation of metastasis phenotypes of non-small cell lung cancer cells by 17-allylamino 17-demethoxy geldanamycin.
Nguyen DM; Desai S; Chen A; Weiser TS; Schrump DS
Ann Thorac Surg; 2000 Dec; 70(6):1853-60. PubMed ID: 11156083
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
Sawai A; Chandarlapaty S; Greulich H; Gonen M; Ye Q; Arteaga CL; Sellers W; Rosen N; Solit DB
Cancer Res; 2008 Jan; 68(2):589-96. PubMed ID: 18199556
[TBL] [Abstract][Full Text] [Related]
6. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative.
Hollingshead M; Alley M; Burger AM; Borgel S; Pacula-Cox C; Fiebig HH; Sausville EA
Cancer Chemother Pharmacol; 2005 Aug; 56(2):115-25. PubMed ID: 15791458
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG.
Hasenstein JR; Shin HC; Kasmerchak K; Buehler D; Kwon GS; Kozak KR
Mol Cancer Ther; 2012 Oct; 11(10):2233-42. PubMed ID: 22896668
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma.
Inoue K; Slaton JW; Perrotte P; Davis DW; Bruns CJ; Hicklin DJ; McConkey DJ; Sweeney P; Radinsky R; Dinney CP
Clin Cancer Res; 2000 Dec; 6(12):4874-84. PubMed ID: 11156247
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effects of radiolabeled 17-allylamino-17-demethoxygeldanamycin on human H460 nonsmall-cell lung carcinoma xenografts in mice.
Sun J; Liu L; Jiang X; Chen D; Huang Y
Cancer Biother Radiopharm; 2010 Apr; 25(2):155-64. PubMed ID: 20423228
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma.
Xu G; Pan J; Martin C; Yeung SC
J Clin Endocrinol Metab; 2001 Apr; 86(4):1769-77. PubMed ID: 11297616
[TBL] [Abstract][Full Text] [Related]
11. The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway.
Ui T; Morishima K; Saito S; Sakuma Y; Fujii H; Hosoya Y; Ishikawa S; Aburatani H; Fukayama M; Niki T; Yasuda Y
Oncol Rep; 2014 Feb; 31(2):619-24. PubMed ID: 24317439
[TBL] [Abstract][Full Text] [Related]
12. Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT.
Sain N; Krishnan B; Ormerod MG; De Rienzo A; Liu WM; Kaye SB; Workman P; Jackman AL
Mol Cancer Ther; 2006 May; 5(5):1197-208. PubMed ID: 16731752
[TBL] [Abstract][Full Text] [Related]
13. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants.
McDaid HM; Lopez-Barcons L; Grossman A; Lia M; Keller S; Pérez-Soler R; Horwitz SB
Cancer Res; 2005 Apr; 65(7):2854-60. PubMed ID: 15805287
[TBL] [Abstract][Full Text] [Related]
15. LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.
Yang C; Wang H; Zhang B; Chen Y; Zhang Y; Sun X; Xiao G; Nan K; Ren H; Qin S
J Exp Clin Cancer Res; 2016 Sep; 35(1):158. PubMed ID: 27737687
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Ohba S; Hirose Y; Yoshida K; Yazaki T; Kawase T
J Neurosurg; 2010 Jan; 112(1):33-42. PubMed ID: 19408974
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with paclitaxel and thalidomide inhibits angiogenesis and growth of human colon cancer xenograft in mice.
Fujii T; Tachibana M; Dhar DK; Ueda S; Kinugasa S; Yoshimura H; Kohno H; Nagasue N
Anticancer Res; 2003; 23(3B):2405-11. PubMed ID: 12894521
[TBL] [Abstract][Full Text] [Related]
19. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001.
Münster PN; Basso A; Solit D; Norton L; Rosen N
Clin Cancer Res; 2001 Aug; 7(8):2228-36. PubMed ID: 11489796
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]